Replimune Group, Inc. has disclosed a significant transaction involving its director, Joseph P. Slattery. According to a recent filing, Slattery sold 5,200 shares of the company’s common stock on November 9, 2026. This move is notable as it reflects ongoing activity within the biological products sector, where Replimune operates.
Replimune Group, Inc. is a company focused on developing innovative therapies in the field of biological products, specifically those that do not involve diagnostic substances. The company is publicly traded under the ticker REPL on the Nasdaq exchange. As a smaller reporting company, Replimune is categorized as a non-accelerated filer, which may affect its reporting requirements.
The recent filing, with accession number 0001104659-26-125235, details Slattery's transaction, which was executed at a price of $21.80 per share. Following this sale, Slattery retains ownership of 1,467 shares in the company. This transaction is classified under Form 4, which reports changes in ownership of securities by company insiders.
This development may have implications for Replimune's stakeholders, including investors and employees. The sale of shares by a director can often raise questions about the company's future direction and performance. As the biological products industry continues to evolve, Replimune's actions will be closely monitored by competitors and analysts alike.
The filing does not specify what actions may follow this transaction, leaving stakeholders to speculate on the potential impacts on the company's strategy and operations moving forward.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




